scholarly journals The prognostic value of preoperative serum albumin in patients with bladder urothelial carcinoma undergoing transurethral resection of bladder tumor

Medicine ◽  
2021 ◽  
Vol 100 (27) ◽  
pp. e26548
Author(s):  
Chen Shen ◽  
Kechong Zhou ◽  
Wei Wang ◽  
Yue Zhang ◽  
Xiaoqiang Liu
2014 ◽  
Vol 3 (6) ◽  
pp. 502 ◽  
Author(s):  
Kaushik Saha ◽  
Arpita Saha ◽  
Chhanda Datta ◽  
Uttara Chatterjee ◽  
Suchandra Ray ◽  
...  

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Shuxiong Zeng ◽  
Anwei Liu ◽  
Lihe Dai ◽  
Xiaowen Yu ◽  
Zhensheng Zhang ◽  
...  

2018 ◽  
Vol 38 (4) ◽  
Author(s):  
Jing Liu ◽  
Fang Wang ◽  
Shaohong Li ◽  
Wenhui Huang ◽  
Yanjuan Jia ◽  
...  

Preoperative serum albumin has been considered to be closely correlated with the prognosis of various cancers, including urothelial carcinoma (UC). However, to date, this conclusion remains controversial. The aim of this meta-analysis is to investigate the prognostic significance of preoperative serum albumin in UC. A literature search was performed in PubMed, Web of Science, Embase, and Cochrane Library up to 4 July 2017. Herein, a total of 15506 patients from 23 studies were enrolled in our meta-analysis. Decreased preoperative serum albumin level predicted poor overall survival (OS) (HR = 1.88, 95% CI: 1.44–2.45, P<0.0001), cancer-specific survival (CSS) (HR = 2.03, 95% CI: 1.42–2.90, P=0.0001), recurrence-free survival (HR = 1.85, 95% CI: 1.15–2.97, P=0.01), 30-day complications (30dCs) after surgery (odds ratio (OR) = 1.93, 95% CI: 1.16–3.20, P=0.01), and 90-day mortality after surgery (OR = 4.24, 95% CI: 2.20–8.16, P<0.001). The subgroup analyses indicated that low preoperative serum albumin level is still positively associated with a worse prognosis of UC based on ethnicity, cut-off value, tumor type, analyses type, and sample size. Our meta-analysis indicated that reduced preoperative serum albumin level was a predictor of poor prognosis of UC.


2021 ◽  
Vol 11 ◽  
Author(s):  
Zhongru Fan ◽  
Zhe Zhang ◽  
Chiyuan Piao ◽  
Zhuona Liu ◽  
Zeshu Wang ◽  
...  

BackgroundAlternative splicing (AS) is an indispensable post-transcriptional modification applied during the maturation of mRNA, and AS defects have been associated with many cancers. This study was designed to thoroughly analyze AS events in bladder urothelial carcinoma (BLCA) at the genome-wide level.MethodsWe adopted a gap analysis to screen for significant differential AS events (DASEs) associated with BLCA. DASEs with prognostic value for OS and the disease-free interval (DFI) were identified by Cox analysis. In addition, a differential AS network and AS clusters were identified using unsupervised cluster analysis. We examined differences in the sensitivity to chemotherapy and immunotherapy between BLCA patients with high and low overall survival (OS) risk.ResultsAn extensive number of DASEs (296) were found to be clinically relevant in BLCA. A prognosis model was established based prognostic value of OS and DFI. CUGBP elav-like family member 2 (CELF2) was identified as a hub splicing factor for AS networks. We also identified AS clusters associated with OS using unsupervised cluster analysis, and we predicted that the effects of cisplatin and gemcitabine chemotherapy would be different between high- and low-risk groups based on OS prognosis.ConclusionWe completed a comprehensive analysis of AS events in BLCA at the genome-wide level. The present findings revealed that DASEs and splicing factors tended to impact BLCA patient survival and sensitivity to chemotherapy drugs, which may provide novel prospects for BLCA therapies.


Sign in / Sign up

Export Citation Format

Share Document